Mechanism of Fibroblast Growth Factor 21 in Cardiac Remodeling

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 7

PMID 37416922

Authors

Zeyu Zhao

Xuemei Cui

Zhangping Liao

Affiliations

Soon will be listed here.

Abstract

Cardiac remodeling is a basic pathological process that enables the progression of multiple cardiac diseases to heart failure. Fibroblast growth factor 21 is considered a regulator in maintaining energy homeostasis and shows a positive role in preventing damage caused by cardiac diseases. This review mainly summarizes the effects and related mechanisms of fibroblast growth factor 21 on pathological processes associated with cardiac remodeling, based on a variety of cells of myocardial tissue. The possibility of Fibroblast growth factor 21 as a promising treatment for the cardiac remodeling process will also be discussed.

Citing Articles

IL-17 is associated with disease severity and targetable inflammatory processes in heart failure.

Baumhove L, van Essen B, Dokter M, Zijlstra S, Deiman F, Laman J ESC Heart Fail. 2024; 11(6):3530-3538.

PMID: 39031992 PMC: 11631355. DOI: 10.1002/ehf2.14968.

Hypertensive Heart Disease: A Narrative Review Series-Part 3: Vasculature, Biomarkers and the Matrix of Hypertensive Heart Disease.

Nemtsova V, Vischer A, Burkard T J Clin Med. 2024; 13(2).

PMID: 38256639 PMC: 10816030. DOI: 10.3390/jcm13020505.

References

Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y . Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin Sci (Lond). 2016; 130(8):625-41. DOI: 10.1042/CS20150623. View

Chen M, Zhong J, Wang Z, Xu H, Chen H, Sun X . Fibroblast Growth Factor 21 Protects Against Atrial Remodeling via Reducing Oxidative Stress. Front Cardiovasc Med. 2021; 8:720581. PMC: 8542911. DOI: 10.3389/fcvm.2021.720581. View

Chou R, Huang P, Hsu C, Chang C, Leu H, Huang C . Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction. Sci Rep. 2016; 6:33953. PMC: 5030655. DOI: 10.1038/srep33953. View

Porter K, Turner N . Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009; 123(2):255-78. DOI: 10.1016/j.pharmthera.2009.05.002. View

Zhang Y, Liu D, Long X, Fang Q, Jia W, Li H . The role of FGF21 in the pathogenesis of cardiovascular disease. Chin Med J (Engl). 2021; 134(24):2931-2943. PMC: 8710326. DOI: 10.1097/CM9.0000000000001890. View

Li S, Yu Y, Li L, Wang W, Li D . Treatment of CIA Mice with FGF21 Down-regulates TH17-IL-17 Axis. Inflammation. 2015; 39(1):309-319. DOI: 10.1007/s10753-015-0251-9. View

Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J . Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010; 106(7):1253-64. PMC: 2855780. DOI: 10.1161/CIRCRESAHA.109.213116. View

Kawakami R, Sunaga H, Iso T, Kaneko R, Koitabashi N, Obokata M . Ketone body and FGF21 coordinately regulate fasting-induced oxidative stress response in the heart. Sci Rep. 2022; 12(1):7338. PMC: 9072431. DOI: 10.1038/s41598-022-10993-4. View

Dai D, Hsieh E, Liu Y, Chen T, Beyer R, Chin M . Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc Res. 2011; 93(1):79-88. PMC: 3243039. DOI: 10.1093/cvr/cvr274. View

10.

Rijzewijk L, van der Meer R, Lamb H, W A M de Jong H, Lubberink M, Romijn J . Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009; 54(16):1524-32. DOI: 10.1016/j.jacc.2009.04.074. View

11.

Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M . The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med. 2007; 13(5):619-24. DOI: 10.1038/nm1574. View

12.

Gao J, Liu J, Meng Z, Li Y, Hong Y, Wang L . Ultrasound-assisted CF-filled PLGA nanobubbles for enhanced FGF21 delivery and improved prophylactic treatment of diabetic cardiomyopathy. Acta Biomater. 2021; 130:395-408. DOI: 10.1016/j.actbio.2021.06.015. View

13.

Wang X, Song S, Xiao H, Gao P, Li X, Si L . Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells. Cell Physiol Biochem. 2014; 34(3):658-71. DOI: 10.1159/000363031. View

14.

Rabanal-Ruiz Y, Otten E, Korolchuk V . mTORC1 as the main gateway to autophagy. Essays Biochem. 2017; 61(6):565-584. PMC: 5869864. DOI: 10.1042/EBC20170027. View

15.

Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R . Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013; 4:2019. DOI: 10.1038/ncomms3019. View

16.

Talman V, Ruskoaho H . Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016; 365(3):563-81. PMC: 5010608. DOI: 10.1007/s00441-016-2431-9. View

17.

Shi B, Ma M, Zheng Y, Pan Y, Lin X . mTOR and Beclin1: Two key autophagy-related molecules and their roles in myocardial ischemia/reperfusion injury. J Cell Physiol. 2019; 234(8):12562-12568. DOI: 10.1002/jcp.28125. View

18.

Sciarretta S, Maejima Y, Zablocki D, Sadoshima J . The Role of Autophagy in the Heart. Annu Rev Physiol. 2017; 80:1-26. DOI: 10.1146/annurev-physiol-021317-121427. View

19.

Bertero E, Maack C . Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018; 15(8):457-470. DOI: 10.1038/s41569-018-0044-6. View

20.

Stanley W, Lopaschuk G, Hall J, McCormack J . Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997; 33(2):243-57. DOI: 10.1016/s0008-6363(96)00245-3. View